April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
116 citations
,
December 2003 in “Acta Dermato Venereologica” Iressa often causes skin issues like acne and dryness in lung cancer patients.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
September 2025 in “Acta Dermato Venereologica” Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
2 citations
,
November 2024 in “In Silico Pharmacology”
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
1 citations
,
October 2019 in “Journal of Thoracic Oncology” Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.
October 2018 in “Annals of oncology” Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
69 citations
,
February 2021 in “PLoS Computational Biology” Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
January 2024 in “Case Reports in Dermatological Medicine” Baricitinib may effectively treat nail changes in alopecia areata.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
May 2025 in “Reactions Weekly” October 2021 in “Journal of Investigative Dermatology” Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.
105 citations
,
October 2018 in “Nature” A small group of slow-growing cells causes basal cell carcinoma to return after treatment.
40 citations
,
January 2017 in “Intestinal Research” Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.
44 citations
,
August 1996 in “Drugs & Aging” Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.